Present and future treatment options for primary CNS lymphoma

Area of Science:

• Neuro-oncology
• Hematology
• Pharmacology

Background:

• Primary Central Nervous System (CNS) lymphomas are rare, aggressive malignancies with poor outcomes.
• The blood-brain barrier hinders effective drug delivery, leading to short remissions and treatment-related toxicities.
• Despite challenges, prognosis has improved due to advanced treatment strategies.

Purpose of the Study:

• To review current pharmacotherapeutic knowledge for immunocompetent patients with primary CNS lymphomas.
• To discuss predictable future developments in treating these rare cancers.
• To present key findings from important published reports in the field.

Main Methods:

• Literature review of published reports on pharmacotherapy for primary CNS lymphomas.
• Focus on immunocompetent patient populations.
• Analysis of current and future treatment strategies.

Main Results:

• Front-line therapy includes high-dose methotrexate-based polychemotherapy, often with cytarabine or alkylating agents.
• High-dose chemotherapy with autologous stem-cell transplantation shows promise for microscopic disease control.
• Management of intraocular, meningeal, elderly, and relapsed cases remains complex and requires specific approaches.

Conclusions:

• High-dose methotrexate-based chemotherapy is the current standard for primary CNS lymphomas.
• Stem-cell transplantation may improve control of microscopic disease.
• Tailored strategies are crucial for specific patient groups and disease manifestations.